Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).

The CARE-MS I trial (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis), a randomized, rater-blinded study, will compare alemtuzumab to Rebif(R) (interferon beta-1a) in patients with relapsing- remitting multiple sclerosis (MS). Alemtuzumab will be given in two annual cycles; Rebif will be administered three times per week. The CARE-MS I study will include patients who have been diagnosed with relapsing-remitting MS but who have not yet begun treatment with any MS drug. CARE-MS II is scheduled to begin soon and will enroll patients who have continued to experience relapse episodes while on currently available disease-modifying therapies.

Initiation of this Phase 3 program follows the successful completion of the initial treatment period in the Phase 2 trial. Interim results from the Phase 2 trial indicated that alemtuzumab-treated patients experienced a statistically significant reduction compared with Rebif-treated patients in the risk for sustained accumulation of disability and the risk for relapse for 24 months. Results of the primary outcomes from this trial at 36 months are expected to be presented on Oct. 14 by Professor Alastair Compston during the Charcot Award lecture at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis, in Prague.

The CARE-MS I study will enroll up to 525 patients at approximately 60 med
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Tenn. , July 22, 2014 Cumberland ... release second quarter 2014 financial results after the market ... and live Internet webcast will be held on Tuesday, ... discuss the results. To participate in the ... (for international callers).  A rebroadcast of the teleconference will ...
(Date:7/22/2014)... 22, 2014 The National Space Biomedical Research ... for Space Radiation Research (CSRR) under the leadership of ... Associate Professor of Pharmaceutical Sciences within the University of ... of Radiation Health. She is located in ... team of investigators working across four U.S. institutions, to ...
(Date:7/22/2014)... BURLINGTON, Mass. , July 22, 2014  Decision Resources ... in Canada will remain relatively stagnant ... is despite the fact that percutaneous coronary intervention (PCI) volumes ... to other developed markets, such as the United ... growth will be largely driven by the increase in penetration ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3
... ConvaTec, a world-leading developer and marketer ... today announced that Amcare Ltd, a wholly-owned subsidiary of ... (operating as "Trent Direct"), a UK-based company that specialises ... continence care products. As a well-respected ...
... 2011 Experian® today announced that they and ... prescribing company (e-prescribing), with an authentication solution for ... Symantec products will allow DrFirst to securely and ... who are eligible to issue e-prescriptions for controlled ...
Cached Medicine Technology:ConvaTec Announces Acquisition of Trent Direct 2Experian and Symantec Provide DrFirst with Identity Proofing and Authentication Technology 2Experian and Symantec Provide DrFirst with Identity Proofing and Authentication Technology 3Experian and Symantec Provide DrFirst with Identity Proofing and Authentication Technology 4Experian and Symantec Provide DrFirst with Identity Proofing and Authentication Technology 5
(Date:7/22/2014)... of Hematology (ASH) will present the Society,s highest honor, ... in Hematology, to Kanti R. Rai, MD, of the ... for his 50-year career combining landmark clinical leukemia research, ... care. , The Wallace H. Coulter Award for ... who has been a vital contributor to the field ...
(Date:7/22/2014)... WASHINGTON -- Autoimmune disorders may share certain pathogenic mechanisms ... Washington University (GW) researcher Linda Kusner, Ph.D. , ... , This paradigm shifting work shows that the very ... are also expressed in cells that produce autoimmune diseases. ... of Neurology at the GW School of Medicine and ...
(Date:7/22/2014)... 2014 Ticket Down is a reliable ... at Fedex Field in Landover, MD. There has never been ... of international soccer. After the success of the American national soccer ... alive and well. One way that fans of the world’s sport ... with the 2014 Guinness International Champions Cup. The tournament will kick ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
(Date:7/22/2014)... French . ... to step out for a cigarette twice as often as ... those who have the hardest time shaking off the habit ... aware of. , Those insights were among the collective findings ... by a team of researchers based in part at ...
Breaking Medicine News(10 mins):Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Extra exercise helps depressed smokers kick the habit faster 2
... follicles, mouse study shows , , WEDNESDAY, Nov. 21 (HealthDay ... which a mother,s smoking before and after pregnancy might ... , Cigarette smoking during pregnancy has been shown in ... offspring, but this is the first study to offer ...
... Alberta, Nov. 21 What would you do if ... Beel ate properly,never smoked, wasn,t a drinker, exercised and ... young age of 32, he suffered a stroke. In ... a Brain Injury",(published by AuthorHouse -- http://www.authorhouse.com ), ...
... release and,statements are attributed to The American Liver ... to raising awareness,and improving the quality of life ... a statement today expressing its concern over the ... made repeated,use of medicine vials intended for single-patient ...
... about losing employment, survey found , WEDNESDAY, Nov. 21 (HealthDay ... levels of job-related stress, a new study shows. , A ... 1,544 people ages 53 to 85 who worked at least ... over half were male, 87 percent were white, about 8 ...
... body of knowledge to Texas,research center in Fort ... The University of,North Texas Health Science Center [ ... added several new members to its faculty,to build ... manipulative medicine., Anuja Ghorpade has joined the ...
... and Abbott Employees Give More Than $7.2 Million and ... in Communities Across the Country, ABBOTT PARK, Ill., ... out to help their neighbors, providing more than,$7.2 million ... across the country. These employee contributions from the,company,s annual ...
Cached Medicine News:Health News:Smoking Before, After Pregnancy Harms Daughters' Fertility 2Health News:Smoking Before, After Pregnancy Harms Daughters' Fertility 3Health News:Smoking Before, After Pregnancy Harms Daughters' Fertility 4Health News:The Blessing of a Brain Injury: Author Survives Injury to Brain Following Stroke, Uses Injury as Fuel to Overcome Odds 2Health News:The American Liver Foundation Encourages Heightened Awareness of Hepatitis B and C in Light of Recent Events in the News 2Health News:Jobs Don't Stress Most Older Workers 2Health News:UNT Health Science Center Appoints Eight New Faculty Members 2Health News:UNT Health Science Center Appoints Eight New Faculty Members 3Health News:Abbott Employees Give Back to Local Communities This Holiday Season 2Health News:Abbott Employees Give Back to Local Communities This Holiday Season 3
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... LactoSorb® No-Profile Screw and Washer ... for multiple soft tissue re-attachments ... No-Profile Screw and washer provides ... a standard screw and washer ...
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
Medicine Products: